The vision of Life Science Leader is to be an essential business tool for life science executives. Our content is designed to not only inform readers of best practices, but motivate them to implement those best practices in their own businesses.
Issue link: https://lifescienceleadermag.epubxp.com/i/267232
LIFESCIENCELEADER.COM MARCH 2014 63 Simplify your contract manufacturing with process development, cell-culture manufacturing, formulation development, vial and syringe filling and secondary packaging all in one location. Accelerate the delivery of your life-enhancing products to patients, and work with one point of contact and one set of business practices. To see our capabilities videos, visit w w w.youtube.com/user/cookpharmica, or contac t our Business Development team at busdev@cookpharmica.com. SIMPLIFY YOUR CONTRACT MANUFACTURING www.cookpharmica.com ' ( 9 ( /2 3 0 ( 1 7 Ř & / , 1 , & $ / Ř & 2 0 0 ( 5 & , $ / Ř ' 5 8 * 6 8 % 6 7$ 1 & ( Ř ' 5 8 * 3 5 2 ' 8 & 7 k&22. 3+%$'9/6/0$5(1 labeling, Nielsen recommends catering to the lowest common denominator. For example, if a portion of the target audi- ence might have difficulty reading, that factor has to be considered when design- ing the instructions. "There is not a lot of customization for the different patient populations," he says. "I have yet to see anyone produce a pen for a patient in their 20s and another one for patients in their 60s. We may see more of that in the future when companies get more involved with addressing patient subpopulations, but until then we need to do whatever possi- ble to minimize side effects and maximize adherence for all potential patients." START THINKING ABOUT PATIENTS EARLY To ensure patients are a primary concern throughout the development process, they should be a consideration from the very start. "Depending on where a drug is in its life cycle, decisions on technology design should be part of the initial drug develop- ment strategy or as soon as the need for reformulation is identified," notes Robert Becker, chief research officer for Aptalis Pharma. "Of course, we need to ensure a drug is effective and tolerable, but if it can't get to where it needs to go because patients can't tolerate it, or it is delivered in an inefficient dosage form—it is not going to achieve its intended clinical goal." When it comes to decisions about drug delivery technology, time is of the essence. Becker believes incorporating the most appropriate drug technologies from the start also helps optimize life cycle man- agement, making the most of the drug at every stage. "Ultimately, this will enable the drug to bring more value to the patients who use it and greater profitabil- ity to the company that makes it," he adds. One way to make sure all patient con- siderations have been taken into account A better understanding of patient-centric drug delivery will lead to better patient outcomes, which is clearly the overall goal of what we do. R A L P H L I P P President and CEO of Lipp Life Sciences LLC. 0 3 1 4 _ P h a r m a _ B u s i n e s s _ D D . i n d d 2 0314_Pharma_Business_DD.indd 2 2 / 1 9 / 2 0 1 4 2 : 4 5 : 5 2 P M 2/19/2014 2:45:52 PM